Table 3.

Mutations associated with resistance to clofazimine (CFZ) in ≥2 isolates reported by ≥2 studies or ≥3 isolates reported by ≥1 study^a

Gene	aa change [nt]	MIC summary (relative to parent for available isolates)	MIC change by mutant/study	Data summary	References (in order of data in column 4 and separated by semicolons)b
Rv0678	G193 deletion	2–4×	2–4×	23 mutants isolated in vitro from MTB H37Rv	Zhang 20159
Rv0678	G193 insertion	2–4×	2–4×	22 mutant H37Rv isolates	Zhang 20159
Rv0678	R156* [C466T]	≥1–4×	≥1–4×	11 mutant H37Rv isolates	Zhang 20159
Rv0678	C364 insertion	2–4×	2–4×	5 mutant H37Rv isolates	Zhang 20159
Rv0678	S68G [A202G]	2–4×	2–4× (5 isolates); 4× (1 isolate)	6 isolates evolved in vitro	Zhang 2015;9 Andries 201433
Rv0678	S63R [C189A]	4×	4×	5 in vitro selected MTB H37Rv mutants	Hartkoorn 201432
Rv0678	V1A (M1A) [2T>C]	2–8×	8×; 4×; unknown; ≥2×	3 clinical resistance evolution; 2 isolates evolved in vitro	Bloemberg 2015;35+ Hoffman 2016;36+ Somoskovi 2015;47 Zhang 20159
Rv0678	S53L or P	4×	4×; MIC 2–4 mg/L (2 isolates S53P, 1 isolate S53L, unknown parent, MIC breakpoint for CFZ resistance 1.0 mg/L); 2.09 mg/L (no parent)	1 in vitro selected MTB H37Rv mutant; 4 clinical MTB strains	Zhang 2015;9Pang 2017;41Xu 201738/201842
Rv1979c	V351A [T1052C]	4×	4× (2 with Rv0678 ins at nt193)	3 mutant H37Rv isolates	Zhang 20159

^aLow confidence data underlined.

^bA superscript ‘+’ indicates that mmpR or pepQ were not consistently sequenced.